Skip to main content
ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma
ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma
ERC Belgium S.A. (ERC), announced publication of its most recent efficacy data in the May 2022 edition of Frontiers in Oncology.
ERC Belgium balance sheet for the financial year ending 31 Dec 2021
Download the ERC Belgium balace sheet for the financial year ending 31 Dec 2021.
CEO STATEMENT 2021/2022
ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.
12 Month Progress Report 30/04/2019-30/04/2020
LATEST SITUATION – CEO STATEMENT
In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA
Abigail-Alliance Humanitarian of the year award 2019
In recognition of ERC’s commitment, Doctor Stathopoulos has received the Abigail-Alliance award for Humanitarian of the year 2019 for the ERC RTT program and Gliovac/ERC1671. Click...
Decision of National organisation of Medicines of Greece
Approval of Temporary Individual Access to Early Access to the Medicinal Product GLIOVAC in Greece.
12 month progress report 31/08/2017-31/09/2018
ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
New production site in the Netherlands
ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same,...
Approval for open phase II study
ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination
Interest to use our technology for other cancers
Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.
for more details.